Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-t-C6-Pyr-Cer is a **synthetic, water-soluble ceramide analog featuring a pyridinium group** attached to a six-carbon (C6) acyl chain, in the L-threo stereochemistry. It is structurally related to ceramides, a family of sphingolipid metabolites involved in cell signaling. This compound is primarily used as a research tool to investigate ceramide signaling and its interaction with protein targets, specifically the inhibition of the SET protein and activation of the tumor suppressor phosphatase PP2A. Mechanistically, certain ceramide species, including pyridinium D-e-C6-ceramide, act as direct SET binders and **PP2A activators**, while their isomers—including "L" stereoisomers—do not activate PP2A, indicating a strong stereoselectivity in biological activity[2]. No approved clinical or therapeutic use is reported for L-t-C6-Pyr-Cer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-t-C6-Pyr-Cer.